:
Oxidative stress, which results in the damage of diverse biological molecules, is a ubiquitous cellular process
implicated in the etiology of many illnesses. The sulfhydryl-containing tripeptide glutathione (GSH), which is synthesized
and maintained at high concentrations in all cells, is one of the mechanisms by which cells protect themselves from
oxidative stress. N-acetylcysteine (NAC), a synthetic derivative of the endogenous amino acid L-cysteine and a precursor of
GSH, has been used for several decades as a mucolytic and as an antidote to acetaminophen (paracetamol) poisoning. As a
mucolytic, NAC breaks the disulfide bonds of heavily cross-linked mucins, thereby reducing mucus viscosity. In vitro, NAC
has antifibrotic effects on lung fibroblasts. As an antidote to acetaminophen poisoning, NAC restores the hepatic GSH pool
depleted in the drug detoxification process. More recently, improved knowledge of the mechanisms by which NAC acts has
expanded its clinical applications. In particular, the discovery that NAC can modulate the homeostasis of glutamate has
prompted studies of NAC in neuropsychiatric diseases characterized by impaired glutamate homeostasis. This narrative
review provides an overview of the most relevant and recent evidence on the clinical application of NAC, with a focus on
respiratory diseases, acetaminophen poisoning, disorders of the central nervous system (chronic neuropathic pain,
depression, schizophrenia, bipolar disorder, and addiction), cardiovascular disease, contrast-induced nephropathy, and
ophthalmology (retinitis pigmentosa).